PT Siloam International Hospitals Tbk

DB:2LS Stock Report

Market Cap: €1.8b

Siloam International Hospitals Valuation

Is 2LS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 2LS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 2LS (€0.13) is trading below our estimate of fair value (€0.22)

Significantly Below Fair Value: 2LS is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 2LS?

Other financial metrics that can be useful for relative valuation.

2LS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2.7x
Enterprise Value/EBITDA14x
PEG Ratio1.7x

Price to Earnings Ratio vs Peers

How does 2LS's PE Ratio compare to its peers?

The above table shows the PE ratio for 2LS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.6x
RHK RHÖN-KLINIKUM
22.8xn/a€883.6m
M12 M1 Kliniken
39.5x32.2%€250.9m
LIK LIMES Schlosskliniken
31.3xn/a€101.4m
SYAB SYNLAB
25x36.4%€2.3b
2LS Siloam International Hospitals
25.7x14.9%€31.2t

Price-To-Earnings vs Peers: 2LS is good value based on its Price-To-Earnings Ratio (25.7x) compared to the peer average (29.6x).


Price to Earnings Ratio vs Industry

How does 2LS's PE Ratio compare vs other companies in the European Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.4%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a23.4%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 2LS is expensive based on its Price-To-Earnings Ratio (25.7x) compared to the European Healthcare industry average (18.4x).


Price to Earnings Ratio vs Fair Ratio

What is 2LS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

2LS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.7x
Fair PE Ratio38.9x

Price-To-Earnings vs Fair Ratio: 2LS is good value based on its Price-To-Earnings Ratio (25.7x) compared to the estimated Fair Price-To-Earnings Ratio (38.9x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 2LS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.13
€0.16
+19.3%
17.4%€0.19€0.086n/a9
Apr ’25€0.13
€0.16
+26.8%
17.5%€0.19€0.087n/a9
Mar ’25€0.13
€0.16
+27.2%
18.3%€0.19€0.088n/a8
Feb ’25€0.13
€0.16
+21.5%
20.5%€0.19€0.088n/a9
Jan ’25€0.12
€0.15
+25.9%
23.5%€0.19€0.088n/a10
Dec ’24€0.12
€0.16
+25.6%
19.8%€0.20€0.099n/a9
Nov ’24€0.13
€0.15
+11.8%
20.6%€0.20€0.098n/a9
Oct ’24€0.12
€0.13
+8.9%
11.7%€0.16€0.10n/a9
Sep ’24€0.11
€0.13
+15.8%
12.4%€0.15€0.099n/a8
Aug ’24€0.11
€0.13
+23.3%
13.3%€0.15€0.099n/a6
Jul ’24€0.11
€0.12
+9.8%
13.6%€0.14€0.087n/a7
Jun ’24€0.096
€0.12
+24.2%
13.6%€0.14€0.087n/a7
May ’24€0.10
€0.10
+2.7%
24.4%€0.13€0.065€0.138
Apr ’24€0.086
€0.086
+0.2%
17.8%€0.11€0.065€0.138
Mar ’24€0.075
€0.081
+6.7%
12.7%€0.097€0.064€0.138
Feb ’24€0.07
€0.079
+13.6%
12.9%€0.097€0.064€0.137
Jan ’24€0.07
€0.077
+9.7%
13.3%€0.097€0.064€0.128
Dec ’23€0.069
€0.083
+20.2%
14.1%€0.10€0.068€0.128
Nov ’23€0.066
€0.083
+26.6%
14.1%€0.10€0.068€0.138
Oct ’23€0.061
€0.087
+40.8%
9.7%€0.10€0.074€0.127
Sep ’23€0.063
€0.089
+42.8%
9.7%€0.10€0.074€0.117
Aug ’23€0.059
€0.088
+49.3%
10.3%€0.098€0.07€0.117
Jul ’23€0.057
€0.088
+54.6%
10.3%€0.098€0.07€0.117
Jun ’23€0.065
€0.089
+37.1%
9.4%€0.099€0.071€0.0968
May ’23€0.061
€0.09
+48.0%
8.9%€0.10€0.072€0.109

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.